ROIVANT SCIENCES LTD. Cash
ROIVANT SCIENCES LTD. (ROIV) had Cash of $77.09 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:Cash · last filed 2026-08-06
- 2026-06-30: Cash $77.09M.
- 2026-03-31: Cash $44.53M.
- 2025-12-31: Cash $91.94M.
- 2025-09-30: Cash $102.19M.
| Period end | Cash |
|---|---|
| 2026-06-30 | $77.09M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $44.53M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $91.94M 10-Q · filed 2026-02-06 |
| 2025-09-30 | $102.19M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $94.79M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $93.95M 10-K · filed 2026-05-20 |
| 2024-12-31 | $99.08M 10-Q · filed 2025-02-10 |
| 2024-09-30 | $123.48M 10-Q · filed 2024-11-12 |
| 2024-03-31 | $182.66M 10-K · filed 2025-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |